Expert Meeting “Femarelle – First Choice for Menopause”

On 19 June in Borovets was held a meeting between doctors from Bulgaria and Andrea Genazzani MD, Ph.D., President of the International Society of Gynecological Endocrinology and of the European Society of Gynecology, as well as former president of the International Menopausal Association.

At the meeting, led by Prof. Dr. Gennazani, experts discussed the active ingredient of Femarelle, DT56A, as a first line treatment of the symptoms of menopause due to its effect as a selective estrogen receptor modulator. As a SERM, Femarelle relieves menopausal symptoms in the short and long term and increases bone mineral density (agonistic effect) while not having an effect on the uterus or the breast (antagonistic effect). This mechanism of selective tissue activity has been proven and confirmed in clinical and preclinical studies.

The expert committee of leading gynecologists and endocrinologists at the Borovets Summit concluded that Femarelle is a new generation of menopause management therapy, providing a safe and effective solution for relieving vasomotor symptoms, vulvo-vaginal atrophy and bone health. This will allow patients to improve their quality of life and to welcome any new stage in their lives without any worries.

Femarell is now available in three different versions, tailored to the specific needs of the woman in the long transition to menopause and afterwards.

The blue Femarelle® Rejuvenate is suitable for stopping the signs of aging associated with the first hormonal changes before the hot flashes.

The pink Femarelle® Recharge contributes to the rapid alleviation of hot flushes and insomnia, works to limit irritability and improves metabolism. The combination of vitamin B6 with the active ingredient DT56a turns the natural supplement into the first choice for women during menopause.

The orange Femarelle® Unstoppable allows women to continue having healthy bones after menopause. Long-term Femarelle intake improves bone strength and stimulates bone formation, which has been proven in clinical trials. This prevents serious consequences such as osteopenia and osteoporosis fractures.